ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016
ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner.Communications biology · 2026Article
- MCDHGN: heterogeneous network-based cancer driver gene prediction and interpretability analysis.Bioinformatics (Oxford, England) · 2024Article
- Estrogen receptor-α signaling in post-natal mammary development and breast cancers.Cellular and molecular life sciences : CMLS · 2021Review
- Article
- Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.Cancer letters · 2019Article
- Principles of digital PCR and its applications in current obstetrical and gynecological diseases.American journal of translational research · 2019Review
- The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.Hormones & cancer · 2018Review
- Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Cancer research · 2017Article
- Detection of Activating Estrogen Receptor Gene (Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.Oncogene · 2017Review
- ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg".JAMA oncology · 2016Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Wang and colleagues demonstrate that digital droplet PCR (ddPCR) identified ESR1 mutations in 7% of primary breast cancers. ESR1 mutations were also readily detected in metastatic tissues and circulating tumor DNA in the blood. These results suggest that ddPCR may be amendable for monitoring tumor burden, and to predict relapse. See related article by Wang et al., p. 1130.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.